Clinical trials: Verruca Vulgaris
Common Warts, Common Warts (Verruca Vulgaris)
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy and safety of YCANTH (VP-102)…
- Conditions
- Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
- Trial name
- COVE-2 (NCT07246590)
- Testing
- VP-102, Vehicle
- Where
- 17 sites in United States
- Volunteers
- 302 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Common Warts (Verruca Vulgaris), Common Warts
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
People who participated in either the COVE-2 or COVE-3 study for common warts, may be eligible to enroll into this Long Term Follow Up (LTFU) study COVE-4.
- Conditions
- Common Warts (Verruca Vulgaris), Common Warts, Human Papilloma Virus (HPV), Warts
- Trial name
- COVE-4 (NCT07457918)
- Testing
- Cantharidin
- Where
- 12 sites in United States, Japan
- Volunteers
- 250 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Common Warts, Common Warts (Verruca Vulgaris)
Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)
This is a Phase 2, open-label study (Study VP-CW-304; referred to as COVE-5 [Cantharidin and Occlusion in Verruca Epithelium 5]) to evaluate the safety and systemic exposure of YCANTH (VP-102) following a single 24-hour dermal…
- Conditions
- Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
- Trial name
- COVE-5 (NCT07881952)
- Testing
- VP-102
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Warts, Verruca (Warts)
Intralesional Gardasil-9 for the Treatment of Recalcitrant Warts
This study will evaluate whether Gardasil-9, a vaccine normally used to prevent human papillomavirus (HPV) infection, may be effective for treating recurring warts that have not responded to standard treatments.
- Conditions
- Warts, Verruca (Warts), Verruca Vulgaris
- Trial name
- NCT07806617
- Testing
- 9-valent human papillomavirus vaccine, Sterile Saline
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Rush University Medical Center
Common Warts, Common Warts (Verruca Vulgaris)
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-302; referred to as COVE-3 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy and safety of YCANTH (VP-102/TO-208)…
- Conditions
- Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
- Trial name
- COVE-3 (NCT07637734)
- Testing
- VP-102 (US) / TO-208 (Japan), Vehicle (US) / Vehicle (Japan)
- Where
- 20 sites in United States, Japan
- Volunteers
- 300 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Viral Wart, Plantar Wart
Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir
The goal of this clinical trial is to learn if injecting acyclovir (an antiviral drug) or vitamin D3 directly into skin warts works to clear them in people aged 12 and older with common, plantar, flat, or periungual (around the…
- Conditions
- Viral Wart, Plantar Wart, Common Warts (Verruca Vulgaris), Common Wart
- Trial name
- NCT07448844
- Testing
- Intralesional Acyclovir, Intralesional Vitamin D3
- Where
- 2 sites in Pakistan
- Volunteers
- 40 people
- Sponsor
- Riphah International University
Common Warts (Verruca Vulgaris)
New Treatment of Common Wart
this study aims to compare the efficacy and safety of platelet rich fibrin injection versus intralesional vitamin D injection in the treatmentof common warts.
- Trial name
- NCT07543926
- Testing
- PRF group, Vitamin D
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Sohag University
Verruca Vulgaris, Molluscum Contagiosum
Cold Atmospheric Plasma Device Extension Study
Patients between 4-21 years of age with at least one wart or molluscum lesion are eligible to participate in this study. The duration of the study is a minimum of 4 weeks with the maximum duration of monthly treatments for one…
- Trial name
- NCT05937672
- Testing
- Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Medical University of South Carolina
Common Warts (Verruca Vulgaris)
Candin for the Treatment of Common Warts
The goal of this clinical trial is to compare outcome in healthy subjects 12 years of age and older with at least 3, but no more than 20, common warts (Verruca vulgaris) following treatment with Candin or placebo.
- Trial name
- NCT05889845
- Testing
- Candin, Intradermal Solution
- Where
- 18 sites in United States
- Volunteers
- 330 people
- Sponsor
- Nielsen BioSciences, Inc.
Verruca Vulgaris, Warts
Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts
This Phase 2 study has been designed to determine the safety and efficacy of repeated treatment sessions of VDMN-21 patch at two dose strengths as compared to a matched vehicle control patch in subjects with verruca vulgaris
- Conditions
- Verruca Vulgaris, Warts, Common Wart
- Trial name
- NCT05799157
- Testing
- VDMN-21 Patch Low Dose, VDMN-21 Patch High Dose, Vehicle Patch
- Where
- 16 sites in United States
- Volunteers
- 153 people
- Sponsor
- Veradermics, Inc.
Common Wart, Warts Hand
Cantharidin and Occlusion in Verruca Epithelium
This is a Phase 2, open label study (Study number VP-102-105; referred to as COVE-1 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy, safety and tolerability of VP-102 treatment in subjects with common…
- Conditions
- Common Wart, Warts Hand, Warts, Papillomavirus Infections
- Trial name
- COVE-1 (NCT03487549)
- Testing
- VP-102 Cantharidin topical film forming solution, VP-102 Cantharidin, topical film forming solution
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Verruca Vulgaris, Molluscum Contagiosum Skin Infection
Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca
This study is going to test a cold atmospheric plasma device (CAP), in particular a floating electrode-dielectric barrier device (FE-DBD), to treat warts and molluscum.
- Trial name
- NCT05070754
- Testing
- Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP), Cryotherapy, Canthardin Collodion
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Medical University of South Carolina
Verruca Vulgaris, Involucrin
Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study
Vitamin D3 plays important role in keratinocyte differentiation and had been used recently in verruca vulgaris. Aim of the work: To assess the expression of involucrin in verrucae vulgaris before and after injection of vitamin…
- Trial name
- NCT04793529
- Testing
- Cholecalciferol
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Benha University
Verruca Vulgaris, Healthy
Assessment of Squamous Cell Carcinoma antigen2 in Verruca Vulgaris
This study aims to assess the expression of SCCA2 in the skin of patients with warts and to detect its correlation with characteristics of warts.
- Trial name
- NCT05409365
- Testing
- Immunohistochemical staining monoclonal antibodies to SCCA2 (SERPINB4/ SCCA2 antibody)
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sohag University
Verruca Vulgaris
Photodynamic Therapy in Treatment of Verrucae
To assess the efficacy (clinically and dermoscopically) and safety of photodynamic therapy using intralesional injection of 4% methylene blue solution as a photosensitizer with IPL versus IPL only in treatment of warts.
- Trial name
- NCT04620785
- Testing
- methylene blue / IPL, IPL, saline
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Alexandria University
Verruca Vulgaris
Pulsed 1064nm Nd:YAG in the Treatment of Verruca Vulgaris Versus Conventional Therapy With Liquid Nitrogen Cryotherapy
Verruca vulgaris (VV), or the common wart, is a relatively prevalent and often frustrating cutaneous disease to treat. A single, highly effective therapy for the treatment of VV has not been found.
- Trial name
- NCT01609530
- Testing
- Liquid Nitrogen Cryotherapy, Pulsed 1064nm Nd:YAG
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Trinity Health Michigan
Verruca Vulgaris, Common Warts
Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.
The purpose of this study is to determine if ingenol mebutate 0.05% gel is safe and effective in treating common warts on the hands.
- Trial name
- NCT02748902
- Testing
- ingenol mebutate 0.05% gel
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Neal D. Bhatia, MD
Verruca Vulgaris
ALC-919 For The Treatment Of Common Warts
This is a single-center, randomized, double blind, vehicle-controlled phase 2 study of subjects 8 years of age and older with Common Warts (Verruca vulgaris) who desire treatment.
- Trial name
- NCT02483455
- Testing
- 2014-ALC-919-US, Vehicle-Control Topical Solution
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Veloce BioPharma LLC
Verruca Vulgaris
A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin
The purpose of the study was to see if liquid nitrogen, a commonly used treatment for warts, is more effective if it is used alone, or if it is more effective if combined with cantharidin, a topical treatment also commonly used…
- Trial name
- NCT01084824
- Testing
- Liquid nitrogen and cantharidin
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- North Idaho Dermatology
Wart, Common Wart
Clinical Trial Evaluating Efficacy of Duct Tape for Treatment of Warts
This study is a double-blinded, controlled clinical intervention trial to evaluate the efficacy of duct tape occlusions therapy for the treatment of common warts.
- Conditions
- Wart, Common Wart, Verruca Vulgaris, Verruca Plantaris
- Trial name
- NCT00328991
- Testing
- duct tape occlusion therapy
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Minneapolis Veterans Affairs Medical Center